ALLO-ASC-TI
Biologic
ALLO-ASC-TI is one of 28 biologic programs targeting Lateral Epicondylitis. It is currently in development.
1
Indications
1
Total Trials
0
Active Trials
27
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
52 competitors in Lateral Epicondylitis
#DrugCompanyPhaseTrials
1Aleve
Alnylam PharmaceuticalsApproved
Kenalog
BBassett Healthcare
Approved
Xylocaine
MMEDRx USA, Inc.
Approved
Rayos
RRoxane Laboratories
Approved
Aspercreme Warming
AAveritas Pharma, Inc.
Approved
Isotonic Sodium Chloride
Eli LillyApproved
Decadron
AAspen Global Incorporated
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Kenalog
BBausch Health Americas, Inc.
Approved
Kenalog
MMichael Khazzam
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ALLO-ASC-TI. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Company
- AAnterogen Co., Ltd.